Loading...
•
Jun 30, 2023
Edwards Lifesciences Q2 2023 Earnings Report
Reported strong second-quarter double-digit sales growth and made meaningful progress on innovations to improve patient care globally.
Key Takeaways
Edwards Lifesciences reported an 11% increase in sales to $1.53 billion in Q2 2023, with all product groups achieving double-digit constant currency sales growth. Adjusted EPS was $0.66. The company has increased its full-year outlook due to strong first-half performance and improved healthcare staffing.
Q2 sales grew 11 percent to $1.53 billion; constant currency sales grew 12 percent.
All product groups achieved double digit constant currency sales growth in Q2.
Q2 TAVR sales grew 9 percent; constant currency sales grew 10 percent.
Q2 EPS of $0.50 (includes charge from previous IP agreement); adjusted EPS of $0.66.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Edwards Lifesciences expects full year 2023 sales to be in the $5.9 to $6.1 billion range and adjusted earnings per share to be $2.50 to $2.60. For the third quarter of 2023, the company projects total sales to be between $1.44 and $1.52 billion, and adjusted EPS of $0.55 to $0.61.
Positive Outlook
- Full year 2023 sales to be in the $5.9 to $6.1 billion range.
- Full-year total company and TAVR sales growth to be in the 10 to 13 percent range on a constant currency basis.
- TAVR sales of $3.85 to $4.0 billion.
- TMTT sales of $180 to $200 million.
- Surgical Structural Heart sales of $960 million to $1.02 billion.
Challenges Ahead
- For the third quarter of 2023, the company projects total sales to be between $1.44 and $1.52 billion.
- Adjusted EPS of $0.55 to $0.61 for the third quarter of 2023.
- The company's forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.
- Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements.
- Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include risk and uncertainties associated with the COVID pandemic, clinical trial or commercial results or new product approvals and therapy adoption.
Revenue & Expenses
Visualization of income flow from segment revenue to net income